Jupiter Neurosciences, Inc. (JUNS)

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company developing therapies aimed at neuroinflammation and related disorders. Its development work is built on JOTROL, a proprietary formulation of resveratrol designed to improve the compound's absorption and bioavailability compared with conventional resveratrol.

The company is studying JOTROL as a potential treatment for neurological and rare diseases in which inflammation plays a role, including Parkinson's disease and other central nervous system conditions, and it has also pursued consumer longevity products based on the same technology.

Jupiter Neurosciences is based in Jupiter, Florida, and completed its initial public offering on the Nasdaq in late 2024.